Planet Labs
Largest commercial EO constellation. Daily global imaging. Pelican next-gen integrated 2025. Defense, agriculture, insurance, climate.
FINANCIAL HEALTH
CAPITAL & CREDIT PROFILE
Reported fundamentals from SEC XBRL companyfacts. Derived figures carry their formula in the caption.
Latest quarter (Q1 ended 2026-04-30, filed 2026-06-05): revenue $94.2M · net income −$138.9M · cash $368.1M — SEC XBRL.
DEBT TRANCHES (1)
| Tranche | Principal | Rate / spread | Maturity | SEC accession |
|---|---|---|---|---|
| 0.50% Convertible Senior Notes Due 2030 | $460.0M | 0.50% | 2030-10-15 | 0001193125-26-258304 |
| Total (unmatured) | $460.0M |
Total = sum of listed unmatured tranche principal. Extracted from SEC filings; tranche-level, not exhaustive. Rate / spread = interest_rate_bps ÷ 100 — fixed coupon or floating-rate spread, as extracted from the filing; floating-rate bank debt shows the spread over its reference rate, not all-in cost.
SCHEDULE CREDIBILITY
How well this operator historically meets its own projected dates — launch NETs, company-announced roadmap milestones, and forward-dated facility plans. 100 = says what it does. Discount forward guidance accordingly.
| Source | Events | Late (share) | Median slip | Median slip, late only | Sub-score | On-time allowance |
|---|---|---|---|---|---|---|
| Roadmap milestones | 1 | 0 (0%) | 0 d | — | 100.0 | 30 d |
SCI = 100 × Σ(event credit) ÷ N over the trailing 36 months (2023-07-29 → 2026-07-28). Event credit = 1.0 when the commitment met its announced date (launches: net NET slip < 1 day; roadmap milestones & facility plans: within 30 days of the announced target window — month/year-precision targets count the whole period as on-time), else 30 ÷ (30 + days late beyond that allowance). Sources are pooled, so each source weighs by its event count. Sources: launch NET-change log (LL2 ingest, tracked since 2026-04-17; flown launches in coverage + not-yet-flown launches already slipped ≥1 day; cancelled launches excluded), roadmap registry milestones (company-announced targets, verified provenance only; open milestones past target count as late by days-overdue), facility_plans rows with target_date after announced_at (filing-dated rows excluded). Confidence: high ≥20 events, medium ≥8, low ≥5; no score below 5 events. 100 = says what it does.
Window: 2023-07-29 → 2026-07-28 (36 months) · launch NET log live since 2026-04-17
FLEET & LAUNCH PARTNERS
Satellite operator — does not operate launch vehicles. Primary launch partners: SpaceX (rideshare), Rocket Lab (Electron).
CONSTELLATION ACTIVITY
Constellations operated by this company — live satellite counts from the CelesTrak/GCAT object catalog.
| Constellation | Active | Total | Decayed | Health | Most recent deployment |
|---|---|---|---|---|---|
| Planet (Dove / SkySat) | 123 | 645 | 522 | 19.1% | Nov 28, 2025 |
SECTOR POSITION
RECENT COVERAGE
| Date | Source | Headline |
|---|---|---|
| Jul 23, 2026 | Payload Space | Intel Authorization Act Proposes Limiting Commercial EO Access |
| Jul 17, 2026 | Payload Space | ISU Founder Shares a Vision Beyond Liquidation |
| Jul 07, 2026 | Payload Space | Transporter-17 Sends the First Commercial Nuclear Sat to Orbit |
| Jun 15, 2026 | Payload Space | Space Stocks Dip After SpaceX IPO |
| May 03, 2026 | NASASpaceFlight | SpaceX launches CAS500-2 and 45 other payloads to Sun-synchronous orbit |
REGISTRY DATA
Source: space_company_registry.json · Operator homepage → · Corporate company page (2026 copyright) documents Planet Labs PBC's San Francisco HQ, founders Will Marshall and Robbie Schingler, and satellite constellations (Dove/SuperDove, SkySat, Pelican, Tanage
METHODOLOGY
Launch history and subsystem outcomes aggregate from AstraVeris's launch_events table with Wilson 95% lower bounds on success rates. ARI scores come from the 11-factor composite (/finance/methodology/). Constellation counts derive from the live CelesTrak/GCAT object catalog. Gov contracts from USAspending.gov awards; private deals from deduplicated pipeline deal extraction. Absence of a row means "not tracked" — we never fabricate. See /methodology/ for the full data model and /data-licensing/ for licensing terms.
Not investment advice. For insurance underwriting, verify against primary-source filings and operator investigation reports.